tradingkey.logo

Daxor Corp

DXR
View Detailed Chart
12.760USD
-0.740-5.48%
Close 11/05, 16:00ETQuotes delayed by 15 min
63.60MMarket Cap
--P/E TTM

Daxor Corp

12.760
-0.740-5.48%
Intraday
1m
30m
1h
D
W
M
D

Today

-5.48%

5 Days

-4.99%

1 Month

-8.20%

6 Months

+76.80%

Year to Date

+65.93%

1 Year

+37.20%

View Detailed Chart

TradingKey Stock Score of Daxor Corp

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Daxor Corp's Score

Industry at a Glance

Industry Ranking
28 / 30
Overall Ranking
544 / 4682
Industry
Collective Investments

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Buy
Current Rating
23.500
Target Price
+74.07%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Daxor Corp Highlights

StrengthsRisks
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.22M.
Overvalued
The company’s latest PB is 1.60, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 100.09K shares, decreasing 11.19% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 28.02K shares of this stock.

Daxor Corp News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Daxor Corp Info

Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Ticker SymbolDXR
CompanyDaxor Corp
CEOMr. Michael Richard Feldschuh
Websitehttps://www.daxor.com/
KeyAI